← Back to Search

Monoclonal Antibodies

ANX005 for Autoimmune Hemolytic Anemia

Phase 2
Waitlist Available
Led By Morie Gertz, MD
Research Sponsored by Annexon, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to day 71
Awards & highlights
No Placebo-Only Group

Summary

This trial will test the safety of ANX005, an IV treatment, in people with Warm Autoimmune Hemolytic Anemia. The treatment aims to stop the immune system from attacking red blood cells.

Eligible Conditions
  • Autoimmune Hemolytic Anemia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to day 71
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to day 71 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in disease activity biomarkers
Safety: Treatment-emergent adverse events (TEAEs)
Secondary study objectives
Change in complement system biomarkers
Plasma concentrations

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: ANX005Experimental Treatment1 Intervention
Participants will receive two once-weekly doses of ANX005 at specific time points
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ANX005
2021
Completed Phase 3
~310

Find a Location

Who is running the clinical trial?

Annexon, Inc.Lead Sponsor
13 Previous Clinical Trials
1,473 Total Patients Enrolled
Study DirectorStudy DirectorAnnexon, Inc.
1,271 Previous Clinical Trials
503,919 Total Patients Enrolled
Morie Gertz, MDPrincipal InvestigatorMayo Clinic, Rochester, MN
~2 spots leftby Nov 2025